ArticleThe Lancet. Public health2020
Projected time to elimination of cervical cancer in the USA: a comparative modelling study.
Article in The Lancet. Public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Should routine HPV vaccination programs include males 25-29 years? A systematic review and global meta-analysis.Journal of translational medicine · 2025Pooled it
- Clinical Validation of a Vaginal Cervical Cancer Screening Self-Collection Method for At-Home Use: A Nonrandomized Clinical Trial.JAMA network open · 2025Trial
- Adapting Sexual Behavior Survey Data to Parameterize an Agent-Based Model of Human Papillomavirus (HPV) Transmission.Medical decision making : an international journal of the Society for Medical Decision Making · 2026Article
- Optimal cervical cancer screening strategies for unvaccinated and HPV-vaccinated cohorts in the United States: a comprehensive comparative modeling analysis.Lancet regional health. Americas · 2026Article
- Correlates of Integrated Human Papillomavirus Vaccination and Cervical Cancer Screening Protection in U.S. Low-Income Women.Vaccines · 2026Article
- Public health impact of increasing human papillomavirus vaccination and cervical cancer screening.Journal of the National Cancer Institute · 2026Article
- Modelling the time to cervical cancer elimination in England: strategies for achieving elimination by 2040.BMJ public health · 2026Article
- Innovations in HPV vaccination and their role in global cervical cancer control: a review.Therapeutic advances in vaccines and immunotherapy · 2026Review
- Cervical cancer burden in India: A descriptive epidemiological study and policy insights.Global epidemiology · 2025Article
- Modeling cervical cancer elimination: a pathway to inform policy decisions.Cancer biology & medicine · 2025Article
- National Outcomes of Increasing Cervical Cancer Screening in Federally Qualified Health Centers.JAMA network open · 2025Article
- Article
- Cervical Cancer Screening, HPV Vaccination, and Cervical Cancer Elimination.JAMA network open · 2025Article
- Cervical Cancer Screening Cascade: A Framework for Monitoring Uptake and Retention Along the Screening and Treatment Pathway.Current oncology (Toronto, Ont.) · 2025Review
- Disparities in cervical cancer elimination time frames in the United States: a comparative modeling study.Journal of the National Cancer Institute · 2025Article
- State-level disparities in cervical cancer prevention and outcomes in the United States: a modeling study.Journal of the National Cancer Institute · 2025Article
- Cost-effectiveness analysis of switching from a bivalent to a nonavalent HPV vaccination programme in China: a modelling study.The Lancet regional health. Western Pacific · 2025Article
- Unveiling the functions of five recently characterized lncRNAs in cancer progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Accelerating progress to reduce the cancer burden through prevention and control in the United States.Journal of the National Cancer Institute · 2025Article
- Protocol for a systematic review and meta-analysis of the impact of cervical cancer prevention initiatives in Ghana.PloS one · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundIn May, 2018, the Director-General of WHO issued a global call to eliminate cervical cancer as a public health problem, which will involve ambitious screening and vaccination coverage targets. We aimed to assess the potential for, and timing of, cervical cancer elimination in the USA and whether this could be expedited by adopting ambitious coverage targets, using two cervical cancer simulation models.
methodsIn this modelling study, we used two independently-developed cervical cancer microsimulation models-Harvard and Policy1-Cervix-to estimate changes in the incidence of human papillomavirus (HPV)-induced cervical cancer over time in the USA, including herd effects from vaccination. We compared nine alternative scenarios for prophylactic HPV vaccination and cervical screening scale-up with a status quo scenario that involved no additional interventions in the context of a threshold for cervical cancer elimination of four or fewer cases per 100 000 women-years. We also estimated the number of cervical cancer cases that could be averted between 2019 and 2100 associated with the adoption of ambitious goals for cervical cancer screening and vaccination coverage, and other potential strategies.
findingsUnder status quo assumptions, the Havard and Policy1-Cervix models projected that cervical cancer incidence would decrease to less than four or fewer new cases per 100 000 women-years by the 2038 and 2046, respectively. Scaling up screening coverage to 90% in 2020, was the most effective intervention to expedite time to elimination (10-13-year reduction), averting a mean of 1400-2088 additional cases annually between 2019 and 2100. Increasing HPV vaccination coverage to 90% or vaccinating adults aged 26-45 years had relatively little effect on cervical cancer incidence. Sensitivity analysis using different population structures resulted in differences in time to elimination (range -10 years to +27 years) compared with status quo predictions.
interpretationThe USA is on track to eliminate cervical cancer as a public health problem in the next two to three decades. Time to elimination could be expedited by 10-13 years by achieving higher screening coverage. Targeting of underscreened and under-vaccinated women remains key to achieving cervical cancer elimination for all women.
fundingUS National Cancer Institute.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.